Marsden C D, Marion M H, Quinn N
J Neurol Neurosurg Psychiatry. 1984 Nov;47(11):1166-73. doi: 10.1136/jnnp.47.11.1166.
Twenty-three children (aged less than 18 years) and 17 adults with severe widespread dystonia were treated with high doses of benzhexol (up to 130 mg daily introduced slowly over many weeks). Children tolerated higher doses (median 30 mg/day) than adults (median 20 mg/day). 52% of the children gained useful benefit, many (43%) without unwanted side effects. Such an approach was less successful in adults; 41% gained benefit, but only 35% had no side effects. Twelve adults with severe axial dystonia, and two children with life-threatening generalised dystonia were treated with a combination of a low constant dose of tetrabenazine to which were added pimozide and benzhexol as necessary. The dose of tetrabenazine was aimed at 75 mg daily; pimozide was increased (6 to 25 mg/day) until the dystonia was relieved or Parkinsonism and other side-effects prevented further increments; if necessary benzhexol (6 to 30 mg/day) then was added to control side-effects and to provide additional benefit. 75% of the adults with severe axial dystonia, and one of the two children with life threatening generalised dystonia gained useful benefit from this regime. It is concluded that high dose benzhexol is the present first treatment of choice for children with severe dystonia, and is worth a try in adults but with less expectation of success. When benzhexol treatment alone fails in adults with severe disabling axial dystonia, or in children with life-threatening generalised dystonia, combined therapy with tetrabenazine, pimozide and benzhexol may give valuable symptomatic relief.
23名儿童(年龄小于18岁)和17名患有严重广泛性肌张力障碍的成年人接受了大剂量苯海索治疗(数周内缓慢增加至每日130毫克)。儿童比成年人能耐受更高剂量(儿童中位数为30毫克/天,成年人中位数为20毫克/天)。52%的儿童获得了有益效果,许多(43%)没有出现不良副作用。这种方法在成年人中效果较差;41%的人获得了益处,但只有35%没有副作用。12名患有严重轴性肌张力障碍的成年人以及2名患有危及生命的全身性肌张力障碍的儿童接受了低剂量持续服用丁苯那嗪的联合治疗,并根据需要添加匹莫齐特和苯海索。丁苯那嗪的目标剂量为每日75毫克;增加匹莫齐特的剂量(6至25毫克/天),直到肌张力障碍缓解或出现帕金森症及其他副作用而无法进一步增加剂量;如有必要,再添加苯海索(6至30毫克/天)以控制副作用并提供额外益处。75%患有严重轴性肌张力障碍的成年人以及2名患有危及生命的全身性肌张力障碍儿童中的1名从该治疗方案中获得了有益效果。结论是,高剂量苯海索是目前治疗严重肌张力障碍儿童的首选方法,在成年人中值得一试,但成功的期望较低。当单独使用苯海索治疗严重致残性轴性肌张力障碍的成年人或危及生命的全身性肌张力障碍的儿童失败时,丁苯那嗪、匹莫齐特和苯海索联合治疗可能会显著缓解症状。